title: Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.
abstract: OBJECTIVE
  To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold (BVS) in patients with ST-segment elevation myocardial infarction (STEMI).
  
  
  BACKGROUND
  According to the current guidelines, drug-eluting stents are the treatment of choice in patients with STEMI. BVS represents a new technology capable to restore the native vessel vasomotion and potentially avoiding long-term limitations such as stent thrombosis.
  
  
  METHODS
  From October 2012 to May 2013, patients with evidence of STEMI eligible for BVS implantation were included in this study. Exclusion criteria were not defined.
  
  
  RESULTS
  A total of 25 patients, respectively 31 lesions, were treated. Procedural success was achieved in 97%. Two major adverse cardiac events occurred during hospitalization and follow-up: one patient with cardiogenic shock at the index procedure subsequently died. One patient suffered from instable angina with need for interventional revascularization of a previously untreated vessel. One target vessel failure as a consequence of an intra-procedural dissection was seen. However, no target lesion failure was noted. During 132.7 ± 68.7 days of follow-up none of the patients died.
  
  
  CONCLUSIONS
  Our findings suggest that implantation of BVS in STEMI patients is feasible in this small cohort of highly selected patients. Further evaluation in randomized-controlled trials is needed.
authors.affiliation: Department of Cardiology, Medizinische Klinik I, University of Giessen, Klinikstrasse 33, 35392, Giessen, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Wiebe
authors.forename: Helge
authors.initials: H
authors.lastname: Möllmann
authors.forename: Astrid
authors.initials: A
authors.lastname: Most
authors.forename: Oliver
authors.initials: O
authors.lastname: Dörr
authors.forename: Kay
authors.initials: K
authors.lastname: Weipert
authors.forename: Johannes
authors.initials: J
authors.lastname: Rixe
authors.forename: Christoph
authors.initials: C
authors.lastname: Liebetrau
authors.forename: Albrecht
authors.initials: A
authors.lastname: Elsässer
authors.forename: Stephan
authors.initials: S
authors.lastname: Achenbach
authors.forename: Christian
authors.initials: C
authors.lastname: Hamm
authors.forename: Holger
authors.initials: H
authors.lastname: Nef
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D000068338:Everolimus; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D054457:Tissue Scaffolds; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D000068338:Everolimus; D020123:Sirolimus